Vaidya Sane

- There is no explicit mention of any new fundraising through debt in the call transcript. - Dr. Rohit Madhav Sane mentioned preferential share allotment subscription for himself expected to finalize within a month, with a dilution of less than 5%. - The preferential allotment funds might be used for capex related to hospital bed additions, especially at Khopoli hospital. - No other specific equity or debt fundraising plans were disclosed for current or future periods. - The company appears to focus on internal accruals and conservative revenue guidance for growth and CAPEX.

- Khopoli hospital: Plans to add 80 more beds on adjacent land over 12-18 months, in phases of 20-40 beds; estimated cost Rs. 8-10 crores. Awaiting government permissions (~1 month). - Nagpur hospital: Planning an addition of 20 beds in next 12-18 months. - Expansion focus on acquiring existing hospitals or resorts and converting them into Madhavbaug facilities through a franchise-like model, targeting North India, Gujarat, and South India. - Future plan includes adding 40 to 60 beds in Khopoli and Kondhali hospitals within the next 12-18 months. - Expansion being funded through preferential allotment and internal accruals. - No immediate new hospital openings planned for 6-8 months; focus on consolidating existing hospital capacity and marketing. - Long-term vision: Add 10 hospitals and about 1,000 clinics by 2030 with emphasis on rural areas.

- Conservative revenue guidance for FY25: around Rs. 97 to 100 crores, similar to last year’s turnover. - EBITDA margins expected to sustain or improve due to cost efficiencies (HR cost reduction, professional fees optimization, and controlled COGS). - Expansion plans for hospitals include adding 40-60 beds each at Khopoli and Kondhali hospitals within 12-18 months. - Long-term vision to add 10 more hospitals, focusing on acquisitions and franchise-like expansions, especially in North India, Gujarat, and South India. - Plans to establish about 1,000 clinics, 10 hospitals, and 5,000 outpatient departments by 2030, targeting rural areas. - FMCG (Madhavprash) expected to grow gradually with marketing ramp-up and increased retail inquiries. - Marketing efforts are being optimized, with a strong focus on treatment-first approach to drive patient volume growth. - Potential patient surge anticipated with Ayushman Bharat's Ayurvedic coverage, supported by expanding infrastructure and NABH accreditation.

- The company expects a conservative revenue of around Rs. 97-100 crores for the full year FY25, similar to last year’s turnover. - EBITDA margins are expected to sustain and potentially improve beyond current levels due to optimized HR costs, reduced COGS (22-24%), and controlled professional fees. - PAT is projected to rise significantly, with a potential increase from Rs. 2.3 crores (last year) to Rs. 7-8 crores for the full year. - EBITDA margin improvement is anticipated as topline grows since fixed costs like HR and professional fees won't increase proportionally. - A 700% profit jump is forecasted for the full year compared to the previous year. - Expansion plans include adding 40-60 beds in existing hospitals within 12-18 months, aiming for growth primarily in hospital business due to higher margins. - FMCG business growth is gradual, focusing on increasing sales of products like Madhavprash, with marketing plans to scale up sales in the near term.

The transcript does not explicitly mention details about the current or expected order book or any pending orders for Vaidya Sane Ayurved Laboratories Limited. However, some relevant points related to business growth and operations are: - The company is focused on expanding hospital beds by 40 to 60 beds over the next 12 to 18 months. - Plans to increase hospital infrastructure specifically in Khopoli and Kondhali hospitals. - Franchise hospital model discussions are ongoing, indicating future expansion possibilities. - Clinics utilization currently at 45-50% capacity with potential to accommodate 3 times more patients. - Marketing campaigns are being optimized to increase patient inflow and revenues. - EBITDA margins expected to improve with increasing topline. - FMCG business (Madhavprash) sales showing growth potential with online sales expanding. There is no detailed mention of quantifiable order book or pending order values in the call.